Moreover, through correlation analysis between prognostic risk genes and chemotherapeutic drugs, we found that low expression of LILRA2 in liver cancer patients may be an important reason for their insensitivity to chemotherapeutic drugs and poor therapeutic efficacy. This evidence concerns the gene LILRA2 and liver cancer.